Standard Chem & Pharm CO., LTD. (1720.TW)
TWD 61.0
(-2.09%)
TWD 61.0
(-2.09%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 222.97 Million TWD | -46.75% |
| 2022 | 418.69 Million TWD | 44.56% |
| 2021 | 289.63 Million TWD | 43.63% |
| 2020 | 201.65 Million TWD | 39.93% |
| 2019 | 144.11 Million TWD | -5.36% |
| 2018 | 152.28 Million TWD | -18.7% |
| 2017 | 187.31 Million TWD | 295.87% |
| 2016 | 47.31 Million TWD | -77.8% |
| 2015 | 213.16 Million TWD | 17.94% |
| 2014 | 180.75 Million TWD | 42.32% |
| 2013 | 127 Million TWD | 217.5% |
| 2012 | 40 Million TWD | 33.33% |
| 2011 | 30 Million TWD | -86.53% |
| 2010 | 222.69 Million TWD | -30.25% |
| 2009 | 319.27 Million TWD | 216.83% |
| 2008 | 100.77 Million TWD | -34.76% |
| 2007 | 154.45 Million TWD | 56.68% |
| 2006 | 98.58 Million TWD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 429.43 Million TWD | -6.62% |
| 2024 Q2 | 193.46 Million TWD | -7.09% |
| 2023 Q4 | 222.97 Million TWD | -34.98% |
| 2023 FY | 222.97 Million TWD | -46.75% |
| 2023 Q1 | 392 Million TWD | -6.38% |
| 2023 Q2 | 370.51 Million TWD | -5.48% |
| 2023 Q3 | 342.95 Million TWD | -7.44% |
| 2022 Q2 | 292.35 Million TWD | -1.27% |
| 2022 FY | 418.69 Million TWD | 44.56% |
| 2022 Q4 | 418.69 Million TWD | -1.3% |
| 2022 Q3 | 424.2 Million TWD | 45.1% |
| 2022 Q1 | 296.13 Million TWD | 2.24% |
| 2021 Q1 | 247.2 Million TWD | 22.59% |
| 2021 FY | 289.63 Million TWD | 43.63% |
| 2021 Q3 | 242.87 Million TWD | -1.8% |
| 2021 Q4 | 289.63 Million TWD | 19.25% |
| 2021 Q2 | 247.31 Million TWD | 0.05% |
| 2020 Q3 | 206.04 Million TWD | 43.74% |
| 2020 FY | 201.65 Million TWD | 39.93% |
| 2020 Q1 | 145.99 Million TWD | 1.3% |
| 2020 Q4 | 201.65 Million TWD | -2.13% |
| 2020 Q2 | 143.34 Million TWD | -1.81% |
| 2019 Q4 | 144.11 Million TWD | -37.84% |
| 2019 FY | 144.11 Million TWD | -5.36% |
| 2019 Q3 | 231.84 Million TWD | -4.42% |
| 2019 Q2 | 242.55 Million TWD | -4.0% |
| 2019 Q1 | 252.65 Million TWD | 65.91% |
| 2018 FY | 152.28 Million TWD | -18.7% |
| 2018 Q4 | 152.28 Million TWD | -19.77% |
| 2018 Q3 | 189.79 Million TWD | -3.81% |
| 2018 Q2 | 197.3 Million TWD | -3.66% |
| 2018 Q1 | 204.81 Million TWD | 9.34% |
| 2017 Q2 | 152.31 Million TWD | -4.7% |
| 2017 Q4 | 187.31 Million TWD | -3.86% |
| 2017 FY | 187.31 Million TWD | 295.87% |
| 2017 Q3 | 194.83 Million TWD | 27.91% |
| 2017 Q1 | 159.83 Million TWD | 237.8% |
| 2016 FY | 47.31 Million TWD | -77.8% |
| 2016 Q2 | 19.75 Million TWD | -82.75% |
| 2016 Q3 | 18.54 Million TWD | -6.14% |
| 2016 Q4 | 47.31 Million TWD | 155.15% |
| 2016 Q1 | 114.57 Million TWD | -46.25% |
| 2015 Q1 | 185.5 Million TWD | 2.63% |
| 2015 Q4 | 213.16 Million TWD | 271.81% |
| 2015 FY | 213.16 Million TWD | 17.94% |
| 2015 Q3 | 57.33 Million TWD | -61.13% |
| 2015 Q2 | 147.5 Million TWD | -20.49% |
| 2014 FY | 180.75 Million TWD | 42.32% |
| 2014 Q4 | 180.75 Million TWD | 93.83% |
| 2014 Q3 | 93.25 Million TWD | -3.87% |
| 2014 Q2 | 97 Million TWD | 70.18% |
| 2014 Q1 | 57 Million TWD | -55.12% |
| 2013 Q2 | - TWD | -100.0% |
| 2013 Q1 | 10 Million TWD | -75.0% |
| 2013 FY | 127 Million TWD | 217.5% |
| 2013 Q3 | 137 Million TWD | 0.0% |
| 2013 Q4 | 127 Million TWD | -7.3% |
| 2012 Q3 | 30 Million TWD | 0.0% |
| 2012 Q1 | 20 Million TWD | -33.33% |
| 2012 FY | 40 Million TWD | 33.33% |
| 2012 Q4 | 40 Million TWD | 33.33% |
| 2012 Q2 | 30 Million TWD | 50.0% |
| 2011 Q1 | 224.98 Million TWD | 1.03% |
| 2011 Q4 | 30 Million TWD | 200.0% |
| 2011 Q3 | 10 Million TWD | -95.6% |
| 2011 Q2 | 227.26 Million TWD | 1.02% |
| 2011 FY | 30 Million TWD | -86.53% |
| 2010 FY | 222.69 Million TWD | -30.25% |
| 2010 Q4 | 222.69 Million TWD | 0.0% |
| 2009 FY | 319.27 Million TWD | 216.83% |
| 2008 FY | 100.77 Million TWD | -34.76% |
| 2007 FY | 154.45 Million TWD | 56.68% |
| 2006 FY | 98.58 Million TWD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Grape King Bio Ltd | 136.36 Million TWD | -63.518% |
| Maywufa Company Ltd. | 438.97 Million TWD | 49.206% |
| ScinoPharm Taiwan, Ltd. | 570.23 Million TWD | 60.898% |
| Lotus Pharmaceutical Co., Ltd. | 9.51 Billion TWD | 97.658% |
| LIWANLI Innovation Co., Ltd. | 361 Thousand TWD | -61665.374% |
| YungShin Global Holding Corporation | 241.99 Million TWD | 7.861% |
| PhytoHealth Corporation | 17.46 Million TWD | -1177.05% |
| SCI Pharmtech, Inc. | 845.52 Million TWD | 73.629% |
| Formosa Laboratories, Inc. | 2.03 Billion TWD | 89.059% |
| PharmaEssentia Corporation | 954.99 Million TWD | 76.652% |
| Bora Pharmaceuticals Co., LTD. | 3.48 Billion TWD | 93.606% |